Current Report Filing (8-k)
November 06 2019 - 07:39AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 6, 2019
ALBIREO
PHARMA, INC.
(Exact name of
registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation)
|
|
001-33451
(Commission File
Number)
|
|
90-0136863
(IRS Employer
Identification No.)
|
10 Post Office Square,
Suite 1000
Boston, Massachusetts
(Address of principal executive offices)
|
|
02109
(Zip Code)
|
(857)
254-5555
Registrant’s telephone
number, including area code
Not
applicable
(Former name or former
address, if changed since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions:
o
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
Common Stock
|
|
ALBO
|
|
The Nasdaq Capital
Market
|
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in
Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company
o
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. o
Item
2.02 Results of Operations and Financial Condition.
On November 6,
2019, Albireo Pharma, Inc. issued a press release announcing
its financial results for the third quarter ended September 30,
2019 and providing a business update. The full text of the press
release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.
The information in
this Current Report on Form 8-K (including Exhibit 99.1)
shall not be deemed to be “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a
filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
The following
exhibit is furnished with this report:
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ALBIREO
PHARMA, INC.
|
|
|
|
|
Date: November 6,
2019
|
/s/ Ronald H.W.
Cooper
|
|
Ronald H.W.
Cooper
|
|
President and Chief
Executive Officer
|
3
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Dec 2020 to Jan 2021
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Jan 2020 to Jan 2021